Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren+ valsartan) therapy
AS Bomback, Y Rekhtman, PJ Klemmer… - Journal of the American …, 2012 - Elsevier
Aldosterone levels increase in 30%–40% of patients on angiotensin-converting enzyme
inhibitors and/or angiotensin receptor blockers over the long term. This “aldosterone
breakthrough” may carry important clinical consequences given aldosterone's nonepithelial,
pro-fibrotic actions. The renin inhibitor, aliskiren, by suppressing the renin-angiotensin-
aldosterone system (RAAS) proximally, may limit breakthrough compared to conventional
RAAS blockade. This open-label study (NCT01129557) randomized subjects to aliskiren …
inhibitors and/or angiotensin receptor blockers over the long term. This “aldosterone
breakthrough” may carry important clinical consequences given aldosterone's nonepithelial,
pro-fibrotic actions. The renin inhibitor, aliskiren, by suppressing the renin-angiotensin-
aldosterone system (RAAS) proximally, may limit breakthrough compared to conventional
RAAS blockade. This open-label study (NCT01129557) randomized subjects to aliskiren …